Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Growth 2024-2030

Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Growth 2024-2030

Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.

The global Anti-VEGF Drugs for Angiogenesis-related Disease market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Drugs for Angiogenesis-related Disease Industry Forecast” looks at past sales and reviews total world Anti-VEGF Drugs for Angiogenesis-related Disease sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Drugs for Angiogenesis-related Disease sales for 2024 through 2030. With Anti-VEGF Drugs for Angiogenesis-related Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Drugs for Angiogenesis-related Disease industry.

This Insight Report provides a comprehensive analysis of the global Anti-VEGF Drugs for Angiogenesis-related Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Drugs for Angiogenesis-related Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Drugs for Angiogenesis-related Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Drugs for Angiogenesis-related Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Drugs for Angiogenesis-related Disease.

United States market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Anti-VEGF Drugs for Angiogenesis-related Disease players cover Roche, Bayer, Genentech, Novartis and Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Ranibizumab
Brolucizumab
Aflibercept
Conbercept
Faricimab
Others

Segmentation by application
Tumor
Eye Diseases
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Bayer
Genentech
Novartis
Coherus BioSciences Inc.
Regeneron
Qilu Pharmaceutical Co.,Ltd.
Innovent Biologics
Anke Biotechnology
Shenzhen Kangzhe Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceutical Group
Rongchang Biology
Youzhiyou Bio

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-VEGF Drugs for Angiogenesis-related Disease market?

What factors are driving Anti-VEGF Drugs for Angiogenesis-related Disease market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-VEGF Drugs for Angiogenesis-related Disease market opportunities vary by end market size?

How does Anti-VEGF Drugs for Angiogenesis-related Disease break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.